GlaxoSmithKline to buy vaccine developer with 'potentially disruptive technology' in deal worth up to $3.3B

The deal puts GSK in a stronger position to compete with Pfizer and Merck, which are also active in vaccine development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.